These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30107868)

  • 1. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial.
    Li HH; Mycroft S; Christiansen S; Wood DN; Feuersenger H; Pawaskar D; Jacobs I
    Allergy Asthma Proc; 2018 Sep; 39(5):365-370. PubMed ID: 30107868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.
    Zuraw BL; Cicardi M; Longhurst HJ; Bernstein JA; Li HH; Magerl M; Martinez-Saguer I; Rehman SM; Staubach P; Feuersenger H; Parasrampuria R; Sidhu J; Edelman J; Craig T
    Allergy; 2015 Oct; 70(10):1319-28. PubMed ID: 26016741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
    Craig T; Zuraw B; Longhurst H; Cicardi M; Bork K; Grattan C; Katelaris C; Sussman G; Keith PK; Yang W; Hébert J; Hanzlikova J; Staubach-Renz P; Martinez-Saguer I; Magerl M; Aygören-Pürsün E; Farkas H; Reshef A; Kivity S; Neri S; Crisan I; Caballero T; Baeza ML; Hernandez MD; Li H; Lumry W; Bernstein JA; Hussain I; Anderson J; Schwartz LB; Jacobs J; Manning M; Levy D; Riedl M; Christiansen S; Feuersenger H; Pragst I; Mycroft S; Pawaskar D; Jacobs I;
    J Allergy Clin Immunol Pract; 2019; 7(6):1793-1802.e2. PubMed ID: 30772477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
    Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
    J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
    Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
    Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial.
    Riedl MA; Grivcheva-Panovska V; Moldovan D; Baker J; Yang WH; Giannetti BM; Reshef A; Andrejevic S; Lockey RF; Hakl R; Kivity S; Harper JR; Relan A; Cicardi M
    Lancet; 2017 Sep; 390(10102):1595-1602. PubMed ID: 28754491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.
    Pawaskar D; Tortorici MA; Zuraw B; Craig T; Cicardi M; Longhurst H; Li HH; Lumry WR; Martinez-Saguer I; Jacobs J; Bernstein JA; Riedl MA; Katelaris CH; Keith PK; Feussner A; Sidhu J
    Clin Exp Allergy; 2018 Oct; 48(10):1325-1332. PubMed ID: 29998524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
    Fukuda T; Yamagami K; Kawahata K; Suzuki Y; Sasaki Y; Miyagi T; Jacobs I; Lawo JP; Glassman F; Akama H; Hide M; Ohsawa I
    Allergol Int; 2023 Jul; 72(3):451-457. PubMed ID: 36858856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.
    Levy D; Caballero T; Hussain I; Reshef A; Anderson J; Baker J; Schwartz LB; Cicardi M; Prusty S; Feuersenger H; Pragst I; Manning ME
    Pediatr Allergy Immunol Pulmonol; 2020 Sep; 33(3):136-141. PubMed ID: 32953229
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema.
    Bernstein JA; Schwartz L; Yang W; Baker J; Anderson J; Farkas H; Aygören-Pürsün E; Bygum A; Jacobs I; Feuersenger H; Pragst I; Riedl MA
    Ann Allergy Asthma Immunol; 2020 Sep; 125(3):334-340.e1. PubMed ID: 32445670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema.
    Riedl MA; Lumry WR; Li HH; Banerji A; Bernstein JA; Ba M; Bjrkander J; Magerl M; Maurer M; Rockich K; Chen H; Schranz J
    Allergy Asthma Proc; 2016 Nov; 37(6):489-500. PubMed ID: 27931305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema.
    Craig T; Feuersenger H; Pragst I; Dang J
    Allergy Asthma Proc; 2022 May; 43(3):202-208. PubMed ID: 35524357
    [No Abstract]   [Full Text] [Related]  

  • 13. Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks.
    Grant JA; White MV; Li HH; Fitts D; Kalfus IN; Uknis ME; Lumry WR
    Allergy Asthma Proc; 2012; 33(4):348-53. PubMed ID: 22856635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children.
    Lumry W; Manning ME; Hurewitz DS; Davis-Lorton M; Fitts D; Kalfus IN; Uknis ME
    J Pediatr; 2013 May; 162(5):1017-22.e1-2. PubMed ID: 23312695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks--final results of the I.M.P.A.C.T.2 study.
    Craig TJ; Bewtra AK; Bahna SL; Hurewitz D; Schneider LC; Levy RJ; Moy JN; Offenberger J; Jacobson KW; Yang WH; Eidelman F; Janss G; Packer FR; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
    Allergy; 2011 Dec; 66(12):1604-11. PubMed ID: 21884533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management.
    West JB; Poarch K; Lumry WR
    Clin Ther; 2021 Dec; 43(12):2154-2166.e1. PubMed ID: 34879971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema.
    Zhang Y; Tortorici MA; Pawaskar D; Pragst I; Machnig T; Hutmacher M; Zuraw B; Cicardi M; Craig T; Longhurst H; Sidhu J
    CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):158-165. PubMed ID: 29316335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.
    Longhurst H; Cicardi M; Craig T; Bork K; Grattan C; Baker J; Li HH; Reshef A; Bonner J; Bernstein JA; Anderson J; Lumry WR; Farkas H; Katelaris CH; Sussman GL; Jacobs J; Riedl M; Manning ME; Hebert J; Keith PK; Kivity S; Neri S; Levy DS; Baeza ML; Nathan R; Schwartz LB; Caballero T; Yang W; Crisan I; Hernandez MD; Hussain I; Tarzi M; Ritchie B; Králíčková P; Guilarte M; Rehman SM; Banerji A; Gower RG; Bensen-Kennedy D; Edelman J; Feuersenger H; Lawo JP; Machnig T; Pawaskar D; Pragst I; Zuraw BL;
    N Engl J Med; 2017 Mar; 376(12):1131-1140. PubMed ID: 28328347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study.
    Li HH; Zuraw B; Longhurst HJ; Cicardi M; Bork K; Baker J; Lumry W; Bernstein J; Manning M; Levy D; Riedl MA; Feuersenger H; Prusty S; Pragst I; Machnig T; Craig T;
    Allergy Asthma Clin Immunol; 2019; 15():49. PubMed ID: 31485239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study.
    Martinez-Saguer I; Cicardi M; Suffritti C; Rusicke E; Aygören-Pürsün E; Stoll H; Rossmanith T; Feussner A; Kalina U; Kreuz W
    Transfusion; 2014 Jun; 54(6):1552-61. PubMed ID: 24266596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.